Diarylalkane derivative 1可用于胰腺炎的研究。

NVP-ACC789产品描述：NVP-ACC789 is an inhibitor of VEGFR-1, mVEGFR-2, VEGFR-2, VEGFR-3 ａnd PDGFR-β with IC₅₀s of 0.38, 0.23, 0.02, 0.18, 1.4 μM, respectively.IC50 & Target: IC50: 0.38 μM (VEGFR-1), 0.23 μM (mVEGFR-2), 0.02 μM (VEGFR-2), 0.18 μM (VEGFR-3), 1.4 μM (PDGFR-β)^[1]In Vitro: The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of VEGFR-1, mVEGFR-2, VEGFR-2, VEGFR-3 ａnd PDGFR-β with IC₅₀s of 0.38, 0.23, 0.02, 0.18, 1.4 μM, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM, without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC₅₀ of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME ａnd BAE cell invasion ａnd VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM^[1].In Vivo: NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789^[1].
产品链接：www.medchemexpress.com/NVP-ACC789.html

研究领域：Protein Tyrosine Kinase/RTK

靶点：VEGFRPDGFR

相关产品：BIBF 1120  |  SU5416  |  Crenolanib  |  Apatinib  |  Foretinib  |  SU 5402  |  Dovitinib  |  E-3810  |  Masitinib  |  Linifanib  |  Cediranib  |  CHIR-124  |  LY2784544  |  SAR131675  |  SU14813  |  



公司介绍：MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库，总部位于美国新泽西，分别在瑞典和上海设有欧洲区子公司和亚洲区总代理，营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商， 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域，PI3K、MAPK等近千个细分靶点，超过4000个活性小分子化合物现货，以及GPCR、API、离子通道等超过20种不同类型的化合物库，同时提供从毫克到千克的专业定制合成服务。
MCE 对每批产品都进行严格的LCMS和NMR检验，其产品已被全球近万名客户广泛使用并发表大量文章、；
MCE 定期增加各领域热门抑制剂、激动剂，不断扩增已有化合物库，以满足*新的科研需求；
数千种产品在上海有充足备货，24-48小时内送达客户；
大量产品提供免费试用装；已为全球多个知名企业、院校构建各种定制型化合物库。

更新时间：2024/1/2 10:10:55